NICE "yes" for Gilead's Zydelig, a new class of drug for leukemia
The UK medicines cost watchdog the National Institute for Health can Care Excellence (NICE) today issued final draft guidance recommending that US biotech giant Gilead Sciences’ (Nasdaq: GILD) Zydelig (idelalisib) should be made available on the National Health Service in England and Wales for some adults with chronic lymphocytic leukemia (CLL).
The NICE has recommended idelalisib, when given with another cancer treatment rituximab, for adults with CLL who have a specific genetic change and have not received any other treatment or for all adults with CLL if their cancer has come back less than 24 months after previous treatment. Idelalisib is the first of a new class of drug that work by blocking the signals which help cancerous cells multiply and survive.
Decision follows new economic analysts and price discount
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze